| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Serum CXCL12 was significantly expressed in patients with pancreatic cancer. Especially, its expression was more high in patients with metastasis. Immunohistological analysis demonstrated CXCR4 was expressed at the margin of cancerous lesions which was surrounded by CXCL12-expressed stromal tissue. Pancreatic cancer cell lines stimulated by CXCL12 showed down-regulation of E-cadherin, whereas up-regulation of Vimentin, which are important factors in Epithelial mesenchymal-transition. We generated pancreas-specific CXCR4 knockout mice model, interbred with pancreatic cancer model mice. in these mice, development of pancreatic cancer, metastatic lesion and mortality were significantly low compared to pancreatic cancer model mice. Moreover precancerous lesions, PanIN, also were decreased.
taken together, we demonstrated CXCL12/CXCR4 signal have important role in development of pancreatic cancer.
|
